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ABSTRACT
Objectives To implement non-invasive prenatal testing (NIPT) for fetal aneuploidies with semiconductor sequencing
in an academic cytogenomic laboratory and to evaluate the ﬁrst 15-month experience on clinical samples.
Methods We validated a NIPT protocol for cell-free fetal DNA sequencing from maternal plasma for the detection of
trisomy 13, 18 and 21 on a semiconductor sequencing instrument. Fetal DNA fraction calculation for all samples and
several quality parameters were implemented in the workﬂow. One thousand eighty-one clinical NIPT samples were
analysed, following the described protocol.
Results Non-invasive prenatal testing was successfully implemented and validated on 201 normal and 74 aneuploid
samples. From 1081 clinical samples, 17 samples showed an abnormal result: 14 trisomy 21 samples, one trisomy 18
and one trisomy 16 were detected. Also a maternal copy number variation on chromosome 13 was observed, which
could potentially lead to a false positive trisomy 13 result. One sex discordant result was reported, possibly
attributable to a vanishing twin. Moreover, our combined fetal fraction calculation enabled a more reliable risk
estimate for trisomy 13, 18 and 21.
Conclusions Non-invasive prenatal testing for trisomy 21, 18 and 13 has a very high speciﬁcity and sensitivity. Because
of several biological phenomena, diagnostic invasive conﬁrmation of abnormal results remains required. © 2016 The
Authors. Prenatal Diagnosis published by John Wiley & Sons, Ltd.
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INTRODUCTION
Non-invasive prenatal testing (NIPT) using cell-free fetal
DNA is rapidly being adopted as a screening test for the
detection of fetal aneuploidies of chromosomes 13, 18 and
21. Since the ﬁrst proof of concept studies in 2008,1,2 many
clinical studies have shown that NIPT can detect these
chromosomal aneuploidies with high speciﬁcity and
sensitivity.3–6 Those studies primarily focused on the
implementation of NIPT for high-risk pregnancies.
However, with NIPT outperforming the currently used
screening tools for the detection of fetal aneuploidies, this
test is very likely to replace standard prenatal trisomy 21
screening for all pregnancies in the near future.7–9 Recent
studies have shown that with NIPT, also other autosomal
aneuploidies (other than trisomy 13, 18 and 21) and even
segmental chromosomal aberrations can be detected.10–13
Further validation and clinical studies in larger cohorts are
however warranted to assess the added value, sensitivity
and speciﬁcity of these results.14
Multiple technologies can be applied for performing NIPT.
Shallow whole-genome sequencing can be used for complete
genome proﬁling,1,2 while targeted NIPT makes use of
enrichment strategies to speciﬁcally analyse loci of interest
(chromosome 13, 18 and 21).15–18 For NIPT using whole-
genome sequencing with counting statistics, usually a Z-score
is calculated.1,2,19–22
MostNIPTprotocols based onwhole genome sequencingmake
use of Illumina sequence-by-synthesis technologies. Recently
however, it has been proven that also semiconductor sequencing
is capable of reliably detecting fetal aneuploidies in maternal
plasma.23–25
In this study, we have applied semiconductor sequencing
and further studied the impact of two critical parameters that
should be taken into account when calculating both
speciﬁcity and sensitivity for NIPT, that is, (1) the percentage
of fetal DNA in the pool of maternal cell-free DNA (fetal
fraction) and (2) the standard deviation on normal results,
and hence, the amount of sequencing reads.
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Gestational age andmaternal weight are key characteristics that
inﬂuence the fetal DNA fraction.26,27 Because a low fetal fraction
leads to a dramatic decrease in sensitivity, fetal fraction
assessment is of utmost importance.28 The most convenient
measurement of fetal fraction is based on the presence of the Y
chromosome in the plasma sample (FF-Y). Evidently, this fetal
fraction calculation is only possible for pregnancies with a male
fetus. Other methods for fetal fraction measurements rely on
single nucleotide polymorphism differences between maternal
and fetal DNA. These calculations, however, mostly require
additional testing, hence, rendering the overall test more costly.
Interestingly, fetal cell-free DNA fragments are overall shorter
than the corresponding maternal cell-free DNA fragments.29,30
This inherent information can be used for fetal DNA fraction
measurements and eliminates the need of an additional test for
fetal fraction measurement.31 Recently, Kim et al. developed a
new strategy, called seqFF, for fetal fraction calculation.32 This
method is based on the fact that the genomic origin or
representation of cfDNA from fetal and maternal origin differs
slightly. The method being described uses the sequence data that
are investigated for the NIPT analysis itself, making an extra test
for fetal fraction calculation redundant. More importantly, fetal
fraction can be determined for pregnancies with male as well as
female fetuses.
In addition to the issues raised in the preceding texts
concerning sensitivity and speciﬁcity for NIPT, the use of cell-
free fetal DNA in maternal blood also implies some further
inherent issues that can give rise to discordant results with
the genuine fetal karyotype. First, the fetal cfDNA in maternal
plasma is derived from cytotrophoblasts,33 and hence,
(conﬁned) placental mosaicism can lead to both false positive
as well as false negative results. Also, maternal mosaicism for
aneuploidies is a potential source for aberrant NIPT
results.34,35 Secondly, yet another possible source for
discordant results are maternal copy number variations
(CNVs)36,37 or maternal malignancies.38–40 Although different
data-analysis methods can be used to overcome part of these
issues, these biological phenomena implicate that NIPT for
chromosomal aneuploidies will always remain a screening test.
In order to further assess the validity of NIPT in relation to
the issues raised in the preceding texts, we have validated
NIPT on 201 normal and 74 aneuploid samples.
Furthermore, we describe our ﬁndings in >1000 samples in
a diagnostic setting.
MATERIALS AND METHODS
Validation and patient cohort
The validation cohort consists of 201 euploid and 74
aneuploid samples respectively that showed a normal
aneuploid karyotype after invasive testing or a normal result
after NIPT performed in a secondary laboratory. After
explaining the study and signing an informed consent form,
10mL of blood samples was collected in Cell-Free DNA
BCT™ tubes (Streck) or EDTA tubes prior to the invasive
procedure. Gestational age ranged from 11 to 32 weeks.
In total, 1081 patient samples have been tested in our centre
during a period of 15months. In Belgium, no reimbursement is
in place yet, and hence, no restriction on the indication for NIPT
is applied. This way, high-risk as well as low-risk patients are
included. Seventeen twin pregnancies were tested: one
monochorionic/monoamniotic, seven monochorionic/
diamniotic and nine dichorionic/diamniotic twins.
cfDNA isolation and sequencing
Maternal blood sampleswere centrifugedwithin 24h of collection
at 1600g for 10min at 4 °C to separate the plasma from the blood
cells. Plasma was transferred to microcentrifuge tubes and
centrifuged at 16 000g for 10min at 4 °C. Supernatant was
transferred to a new microcentrifuge tube and stored at 80 or
20 °C until further processing. cfDNA was extracted from
3.5mL of plasma using the QIAamp® Circulating Nucleic Acid
Kit (Qiagen) following the manufacturer’s instructions. DNA
concentrations weremeasured using the Qubit® dsDNAHS Assay
Kit (Invitrogen, Thermo Fisher), and 5ng of cfDNA was used as
input for library preparation.
Library construction was performed according to the Ion
Plus Fragment Library Kit (Thermo Fisher) with small
adjustments. Brieﬂy, end-repair of the plasma cfDNA was
performed with T4 DNA polymerase and T4 polynucleotide
kinase. Ion Proton compatible adapters with barcodes (Ion
Xpress Barcode Adapters, Thermo Fisher) were ligated to
the cfDNA using DNA ligase. Libraries were ampliﬁed using
Platinum® PCR SuperMix High Fidelity (Thermo Fisher) in a
thermal cycler [5min 95 °C, (15 s 95 °C, 15 s 58 °C, 1min 70 °
C) 9 cycles]. In between, libraries were puriﬁed using
Agencourt AMPure XP beads (Beckman Coulter). After the
ampliﬁcation, double-size selection was performed using
Agencourt AMPure XP beads for removal of residual
adaptors and primers and potential contaminating genomic
maternal DNA. Libraries were quantiﬁed with the Ion
Library Quantitation Kit (Thermo Fisher). Template
preparation and PI V2 or PI V3 chip loading were performed
on Ion Chef™ (Thermo Fisher) using resp. 60 or 70 pM of
equimolar pooled libraries. The samples were sequenced
on an Ion Proton instrument using 400 ﬂows.
Data analysis
Reads were demultiplexed and aligned to the NCBI GRCh37
human genome reference by the Ion Torrent Server (TMAP
aligner). Subsequently, the reads were ﬁltered on MAPQ >30,
and both the Wisecondor algorithm21 as well as the QDNAseq
algorithm19 were used for further downstream analysis. For
the QDNAseq algorithm, the genome was divided in 100 kb
bins, and read counts were calculated for each bin. After
normalization for the total read count (genome wide
average = 1), bin counts were log2 transformed, and the
average bin count per chromosome was calculated. Finally,
mean and standard deviation were calculated for all
autosomes for 201 reference samples. With these values, a Z-
score (standard score) for each chromosome in each sample
could be calculated. QDNAseq values were imported and
processed in Vivar.41 Aberrant results (for all chromosomes)
were manually checked on a comprehensive chromosome
proﬁle by Wisecondor and Vivar to exclude large (maternal)
segmental aberrations.
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Quality parameters
Genome-wide standard deviation. For all samples, a standard
deviation over all autosomal bins normalized by QDNAseq
was calculated. The mean of this standard deviation over all
reference samples was calculated at 0.117, with a standard
deviation of 0.014. The samples with a standard deviation on
their genome wide bincounts >0.160 (=mean + 3 * SD) were
excluded for further analysis and needed resequencing.
Chromosomal standard deviation (Q-score). A second quality
parameter is calculated as the standard deviation on the
absolute value of all autosomal Z-scores, excluding
chromosomes 13, 18 and 21. For the reference set, a mean
Q-score of 0.675 was reached, and a cut-off of 1.36 (=0.675
+ 3 * SD) was deﬁned. The mean and standard deviation on
all bin means for all chromosomes were calculated on all
reference samples (refer to Table S1, Fig. S1).
Sequence reads. We aimed to obtain 10 million sequencing
reads after quality ﬁltering (MAPQ> 30). To achieve this, six
samples were combined on one PI chip. The samples with
<5M reads needed resequencing.
Fetal fraction
Fetal fraction based on Y chromosome-speciﬁc reads (FF-Y). Fetal
fraction for all pregnancies with a male fetus was calculated
as described.2 In brief, after stringent ﬁltering (MAPQ> 50),
the amount of Y-chromosome-speciﬁc reads is normalized
for the total read count, and by a linear model based on both
male and female reference samples, the fetal fraction was
calculated.
Fetal fraction based on genomic representation. For all samples, the
seqFF method was implemented as described by Kim et al.32
Both weighted rank selection criterion (WRSC) as well as elastic
net (Enet) values were calculated. The mean of both was used
as seqFF value.
Fragment length distribution. For each sample, a read length
distribution is generated by measuring the read count for each
length from 25 bp up to 240 bp. The read length distribution is
subsequently corrected for total read count, and fetal fraction
was predicted using the logistic regression model elasticnet
trained on the reference set.31
Finally the average of Enet, WRSC and readlength
predictions were used as combined fetal fraction (cFF)
predictor and compared with FF-Y values.
ISO 15189 accreditation was obtained for the NIPT workﬂow.
RESULTS
Validation study
A reference set of 201 cfDNA samples from normal euploid
pregnancies was tested for validating NIPT for trisomy 21, 18
and 13 (Table S1). On average, 13.6 million uniquely mapped
reads were used for the analysis after quality ﬁltering
(MAPQ> 30) (minimum 5.2 million).
Using the mean and standard deviation per chromosome, a
Z-score for each chromosome in each sample could be calculated.
A Z-score higher than 5 was used as a cut-off for calling trisomy.
A grey zone was deﬁned for samples showing Z-scores between
3 and 5, and repeat analysis was performed before reporting the
results. If the Z-score was again elevated (>3), this sample was
called aberrant. Using the described protocol, all 201 reference
samples showed a Z-score for chromosomes 13, 18 and 21 below
3, yielding a speciﬁcity of 100% in our validation cohort (Table S1).
From themeans and standard deviations in the reference set, a
theoretical calculation of the detection ratio for several fetal
fractions could be made (Figure S2). Sensitivity of NIPT depends
strongly on the fetal DNA fraction in a cfDNA sample. The higher
the fetal fraction, the higher the sensitivity/detection rate of the
test. With a fetal fraction of 4%, 2.68% of trisomy 21 samples will
be missed based on the observed standard deviation on our
reference, while with a fetal fraction of 5%, only 0.08% of trisomy
21 samples will be missed. Because most samples have a fetal
fraction >5% (Figure S3), the sensitivity for most samples is very
high. Based on these observations, we propose that a NIPT result
with a fetal fraction below 4% should be reported with caution
and considered for a second blood sampling.
For the calculation of the sensitivity of NIPT, 52 trisomy 21, 17
trisomy 18 and 5 trisomy 13 samples were analysed (Table S1).
In total, 51 out of 52 trisomy 21 samples showed a Z-score >3.
One trisomy 21 sample had a Z-score of 1.05 (T21_3). This
sample had a fetal fraction of only 2.7%, giving an explanation
for the failed detection of trisomy 21. Two samples were from a
dizygotic twin pregnancy, with a discordant fetal karyotype where
one fetus had a trisomy 21, while the other one had a normal
karyotype following invasive testing (T21_45 and T21_49). In
previous studies, it has been shown that there is a high correlation
between the fetal fraction and the Z-score calculation. 42–44
T21_45 and T21_49 showed a Z-score of 12.21 and 9.50
respectively, while the fetal fraction was 22.52 and 16.19%. For a
full trisomy 21 result, a higher Z-score would be expected based
on the fetal fraction in the sample (Figure 1c). The discrepancy
in Z-score/fetal fraction measurement hence suggests a deviation
from a full trisomy 21 karyotype. The same holds true for T21_23,
where a mosaic trisomy 21 was detected on invasive testing. The
Z-score (5.30) in this positive sample is lower than what is
expected based on the fetal fraction calculation (13.6%).
Sixteen out of 17 trisomy 18 samples showed a Z-score >3 for
chromosome 18. Sample T18_16 had a Z-score of 1.07 with a fetal
fraction of 9.5%; hence, one false negative was present in our
training cohort (refer to supplemental info for additional details).
Out of the ﬁve samples, ﬁve had a correct trisomy 13 call.
In total, we obtained a sensitivity of 98% (95% CI: 94–100%),
94% (95% CI: 88–100%) and 100% for trisomy 21, trisomy 18
and trisomy 13 detection on our validation set.
Fetal fraction calculation
Figure 2 shows length distributions from three samples with a
different fetal fraction. The length plot clearly demonstrates a
shift towards shorter read lengths in samples with a higher fetal
fraction. Although there is a strong correlation between read
length distribution and fetal fraction (r = 0.761, Figure 3a),
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unfortunately, no clear cut-off could be set to point out the 4%
fetal fraction boundary.
For validating the newly described seqFF method,32 a
comparison of fetal fraction calculation based on FF-Y and
seqFF (Enet and WRSC) for 609 pregnancies with male fetuses
was performed. This comparison gives a correlation of r = 0.909
for the seqFF method (0.869 for Enet and 0.909 for WRSC) (
Figure 3b and c). When we combine WRSC, Enet, as well as
the read length prediction on fetal fraction, a Pearson
correlation of 0.926 for this cFF was observed (Figure 4).
Especially for low fetal fractions (<5%), combining these three
methods performed better. For some samples, we observed a
discordance between the FF-Y and cFF method. Dizygotic
twins from different sex can explain the difference in fetal
fraction calculation between FF-Y and cFF in four samples
(ref_114 and T21_45 — Table S1; case_19 and case_20 —
Table 1). In those samples, the fetal fraction based on the Y
chromosome (FF-Y) is about half the fetal fraction based on
the overall cFF method.
To get an overall estimation of the distribution of the fetal
cfDNA fraction, the cFF method was implemented for all
analysed samples (male and female fetuses) (Figure S2). Only
1.8% of all samples show a fetal fraction that is below 4%,
hence, giving less reliable NIPT results. A blood redraw is
indicated for these patients. It is well known that obese women
have a higher risk for lower fetal fractions,26 and indeed with a
BMI above 30, the chance of having a fetal fraction below 4%
raises to 8.7% (p< 0.005) in our cohort.
Clinical samples and special cases
Since the introduction of NIPT at the Center for Medical
Genetics Ghent, 1081 clinical samples have been analysed. In
total, 17 samples showed an abnormal result (Table 1).
In total, 14 trisomy 21 samples were detected by NIPT, 12 of
which could be conﬁrmed by invasive prenatal testing. For two
samples, no invasive follow-up sample was received. For one
patient, we simultaneously received a NIPT sample and CVS
(case_12). NIPT showed a Z-score of 9.32 for chromosome 21
(cFF=14.27%), while FISH on chorion villi revealed a mosaic
karyotype with 40% of investigated cells showing three signals
for chromosome 21. Abnormalities on ultrasound examination
at 15weeks of gestation were suggestive for a fetal trisomy 21,
and subsequent amniocentesis showed a trisomy 21 in all cells
analysed. Case_17 had a Z-score of 4.11 for chromosome 21 and
a fetal fraction of 4.21%. Although this result was in the ‘grey zone’,
an immediate follow-up amniocentesis was performed,
accompanied with a novel blood redraw for NIPT analysis. Both
tests showed a normal result (Z-score of 0.35 for chromosome
21 in blood redraw). No trisomy 21 could be detected on
amniocytes. Five other samples showed a Z-score in the grey zone
(z-scores ranged from 3.03 to 3.35). Upon repeat analysis, all had
Z-scores below 3 and were reported as normal.
Case_14 had a Z-score of 13.78 for chromosome 18, with a FF
of 12.30% (Figure 1b). Wisecondor analysis also showed an
abnormal proﬁle indicative for full trisomy 18. No
Figure 1 There is high correlation between the fetal fraction and the Z-score for aneuploid pregnancies. Z-scores for chromosome 13 (a), 18
(b) and 21 (c) in relation to the fetal fraction for all analysed samples (validation and patient cohort) are shown. Trisomic samples are indicated
as orange dots; euploid samples are indicated as grey dots. There is a high correlation between the fetal fraction and Z-score for samples with
a trisomy 13 (r2 = 0.978) and 21 (r2 = 0.945). Samples with deviation of the expected Z-score are indicated: maternal duplication on
chromosome 13 (case_15, grey triangle), false negative results (T18_16 and T21_3, red dots), discordant trisomy 18 (case_14), twins with
discordant karyotypes (T21_45 and T21_49, orange squares) and mosaic trisomy 21 samples (T21_23 and T21_51, orange triangles)
Figure 2 Fetal cfDNA fragments are shorter than maternal cfDNA.
Read length distribution of three samples with a different fetal
fraction (3, 10 and 19%). The sample with the highest fetal fraction
(solid line, 19%) has more sequencing reads in shorter regions
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abnormalities on ultrasound examination were observed at
11weeks of gestation, and follow-up amniocentesis revealed a
normal fetal karyotype, hence, showing a discordant NIPT
result for trisomy 18. NIPT on a second blood sample again
showed a positive result for trisomy 18 (Z18 = 13.10), and
sample swap was excluded. The pregnancy is ongoing at time
of writing, and placental tissue at birth is requested to evaluate
a possible placental mosaicism for trisomy 18.
One sample showed a Z-score of 5.41 for chromosome 13,
pointing to a trisomy 13 (case_15, Figure 1a).Wisecondor analysis,
however, revealed that a maternal duplication of ~3Mb in
chromosome band 13q21.33 is responsible for the aberrant
Z-score in the cfDNA sample (Figure 5). We could not evaluate
whether the fetus is also carrier of this duplication, as this result
was not communicated to the patient, and no follow-up invasive
testing was performed.
Case_16 showed aZ-score for chromosome16of 7.9. The sample
was taken at 12weeks (12w5d) of gestation for increased risk for
trisomy 21, 18 and 13 (respectively 1/89, 1> 50, 1> 50) after a ﬁrst
trimester combined test. No ultrasound abnormalities were
apparent at that time point. Although detection of trisomy 16 is
not included in the scope of our NIPT protocol, it was decided to
report this incidental ﬁnding to the patient. Trisomy 16 is usually
a mosaic condition, which is only viable in low-grade percentages.
In prenatal setting, mosaic trisomy 16 has been described in
conﬁned placental mosaicism and can be associated with, for
example, intra-uterine growth retardation.45–49 Extensive
ultrasound follow-up of the pregnancy was advised after this NIPT
result. After genetic counselling, the couple opted for invasive
conﬁrmation of the NIPT result by amniocentesis. Both FISH and
arrayCGH analyses revealed a low-level mosaicism for trisomy 16
of 5–10% in uncultured amniotic cells. Because of complications
related to the invasive procedure, the pregnancy was prematurely
aborted at 19weeks of gestation. FISH analysis on placental and
fetal skin biopsy showed fetal mosaicism for trisomy 16 of 80 and
10% respectively, hence, conﬁrming the NIPT results.
One NIPT result detected amale fetus based on the presence of Y
chromosome material (case 18). However, at term, a healthy baby
girl was born, raising questions about the correctness of the NIPT
result at 11weeks of gestation. Analysis was repeated, yielding the
same results, and STR analysis excluded a sample swap. When
comparing the fetal fraction calculated based on the Y chromosome
(FF-Y) with the fetal fraction based on the cFF method, a large
discrepancy in fetal fraction was noted (6.11% by FF-Y vs 13.51%
by cFF). This deviation in fetal fraction measurements could be a
result of the initial presence of a vanished (male) twin brother.
Retrospectively, however, there was no indication for ultrasound
anomalies nor evidence for an early twin gestation.
DISCUSSION
This article describes the implementation of non-invasive
prenatal testing for chromosomal aneuploidies in an
Figure 3 Both fragment length as well as the genomic representation of cfDNA are good indicators for fetal fraction. Correlation plot between
fetal fraction as calculated on read length (a), elastic net (b) and weighted rank selection criterion (WRSC) (c) versus fetal fraction calculated
based on the amount of Y-chromosome-speciﬁc reads (FF-Y) for 609 euploid male pregnancies. All three predictions give a good estimate of
the fetal fraction with Pearson’s r2 ranging from 0.579 (readlength prediction) to 0.826 (WRSC)
Figure 4 Combined fetal fraction prediction gives a very high
correlation to fetal fraction as predicted by FF-Y. Correlation plot
between combined fetal fraction prediction (combined fetal fraction,
average between readlength prediction, elastic net and WRSC)
versus fetal fraction calculated based on the amount of FF-Y for 609
euploid male pregnancies (grey dots). A very high correlation is
noted between both predictions (Pearson’s r2 = 0.857). Orange dots
represent three euploid, but dizygotic twin pregnancies with both
male and female fetuses (ref_114, case_19 and case_20)
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academic cytogenomic laboratory. To this end, we applied
an in-house developed protocol for shallow whole genome
sequencing of cfDNA on a semiconductor instrument. NIPT
for trisomy 21, 18 and 13 reached a speciﬁcity of 100% and a
sensitivity of 98, 94 and 100% in our validation cohort.
Several other studies describe a lower sensitivity for
chromosome 13; hence, caution should be made given the
limited number of positive validation samples.
Since its implementation, 1081 NIPT samples have been
processed, and 17 showed an abnormal result. Most samples
(14/17, 82%) showed a trisomy 21, but also other abnormalities
have been observed. A total of 12 out of 14 (79%) positive
trisomy 21 samples could be conﬁrmed through subsequent
invasive testing. For two samples, no follow-up information is
available. One mosaic trisomy 21 case was detected and
conﬁrmed by CVS and amniocentesis. A case with discordant
fetal sex shows that biological phenomena such as a vanishing
twin can possibly confound the NIPT results. One case showed
a true mosaicism for trisomy 16, which was conﬁrmed by
amniocentesis and on fetal tissue. Trisomy 16 is the most
common trisomy in spontaneous abortions. While full trisomy
16 has never been observed in live borns, mosaic trisomy has
been reported prenatally and postnatally. Mosaic trisomy 16
is commonly associated with intrauterine growth retardation,
mors in utero or a high risk of abnormal outcome. 45–49
Four months after completion of the study, no false negative
results for trisomy 21, 18 or 13 have been reported, yielding a
sensitivity of 100%.
In this 1000 sample cohort already multiple aberrant,
unusual or discordant ﬁndings were noted, warranting
specialized follow-up and genetic counselling. We therefore
advocate a close collaboration between NIPT providers,
gynaecologists and genetic diagnostic laboratories to reduce
maternal anxiety, enhance counselling and instigate
Table 1 Summary of aberrant and unusual results
Case Indication Result
Reported
NIPT FF-Y cFF Follow-up
Trisomy 21
Case_1 Combined test 1/17 for T21 Z21 = 22.14 Trisomy 21 18.72% 19.44% Conﬁrmed fetal trisomy 21 by amniocentesis
Case_2 Combined test >1/50 for T21 Z21 = 10.26 Trisomy 21 Girl 9.10% Conﬁrmed fetal trisomy 21 by amniocentesis
Case_3 Combined test 1/268 for T21 Z21 = 12.78 Trisomy 21 Girl 13.20% Conﬁrmed fetal trisomy 21 by amniocentesis
Case_4 Not speciﬁed Z21 = 13.79 Trisomy 21 10.28% 10.80% No follow-up — termination of pregnancy
Case_5 Not speciﬁed Z21 = 7.87 Trisomy 21 7.66% 9.77% Conﬁrmed fetal trisomy 21 by amniocentesis
Case_6 Maternal age Z21 = 13.07 Trisomy 21 Girl 10.77% Conﬁrmed fetal trisomy 21 by amniocentesis
Case_7 Combined test 1/141 for T21 Z21 = 23.73 Trisomy 21 Girl 19.10% Conﬁrmed fetal trisomy 21 by amniocentesis
Case_8 Vanishing twin Z21 = 12.6 Trisomy 21 Girl 14.03% Conﬁrmed fetal trisomy 21 by amniocentesis
Case_9 T21 in previous pregnancy Z21 = 7.82 Trisomy 21 Girl 7.88% Conﬁrmed fetal trisomy 21 after spontaneous
abortion
Case_10 Not speciﬁed Z21 = 9.19 Trisomy 21 7.36% 7.90% Conﬁrmed fetal trisomy 21 by CVS
Case_11 NT = 6 mm Z21 = 6.96 Trisomy 21 5.53% 5.87% Conﬁrmed fetal trisomy 21 by amniocentesis
Case_12 NT = 3.3 mm Z21 = 9.32 Trisomy 21 Girl 14.27% 40% mosaic trisomy 21 on CVS, full trisomy 21
by amniocentesis
Case_13 Combined test 1/94 for T21 Z21 = 8.53 Trisomy 21 Girl 8.62% No follow-up – termination of pregnancy –
dysmorphic features on clinical examination
Trisomy 18
Case_14 Not speciﬁed Z18 = 13.78 Trisomy 18 Girl 15.18% Normal female karyotype on amniocentesis,
redraw NIPT Z18 = 13.01
Special results
Case_15 Combined test 1/1590 for T21 Z13 = 5.41 Normal Girl 12.30% Maternal duplication on chromosome 13
Case_16 Combined test 1/89 for T21, >1/50
for T18, >1/50 for T13
Z16 = 7.9 Trisomy 16 7.53% 5.95% True mosaicism trisomy 16
Case_17 Combined test 1/3494 for T21, >1/
50 for T18, >1/50 for T13
Z21 = 4.11 Trisomy 21 5.17% 4.21% Normal male karyotype on amniocentesis,
redraw NIPT Z21 =0.35
Case_18 Maternal age Normal Normal 6.11% 13.51% NIPT reported male, healthy girl born (vanished
twin?)
Case_19 Pregnancy after ART Normal Normal 6.95% 13.90% Dizygotic twin (DC/DA)
Case_20 Pregnancy after ART, combined test 1/
500 for T21
Normal Normal 9.27% 20.39% Dizygotic twin (DC/DA)
NT, nuchal translucency
DC/DA, dichorionic/diamnotic
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conﬁrmatory diagnostic testing. NIPT is a screening test based
on cell-free fetal DNA measurements, and hence, false positive
as well as false negative results are inherent to the technology.
However, several methods can be implemented to reduce
those false positive as well as false negative NIPT results, such
as rigorous quality control, fetal fraction determination and
exclusion of potential confounding maternal CNVs.
In our patient cohort, one sample had a maternal CNV on
chromosome 13 that led to an increased Z-score for chromosome
13 (Z-score 13=5.41), giving a false positive call for trisomy 13.
Generating a comprehensive chromosome proﬁle for this sample
clearly showed a maternal duplication on chromosome 13.
Hence, a normal NIPT result for trisomy 13 was reported. Earlier
studies also showed that maternal CNVs can be a confounding
factor for reliable NIPT interpretation,36,37 advocating for a
comprehensive chromosome proﬁling.
We calculated that a fetal fraction of minimum 4% is crucial to
obtain a sensitivity warranted for reliable NIPT results (Figure
S2). Although a higher sequencing depth can improve the
sensitivity for these low fetal fractions, this does not scale well,
and hence, a repeat blood sample was requested in our
workﬂow. Moreover, a reliable calculation of the fetal fraction
can help in the interpretation of Z-scores in the grey zone, as
they might be indicative for mosaicism or twins with a
discordant result. Because the fetal DNA fraction is low early in
pregnancy and increases as the pregnancy advances, NIPT is
currently performed from 10–11weeks of gestation onwards.50
It has been shown that obese mothers have on average
lower fetal cfDNA fractions.26,27 Indeed, while in the entire
cohort only 1.8% of samples showed a fetal fraction below
4%, this number increased to 8.7% for women with a
BMI> 30. Measuring the fetal fraction in NIPT samples can
give a better estimation on the reliability of NIPT results,
and hence, less false negatives.
Only a limited number of laboratories currently make use of Ion
Torrent sequencing technology for NIPT.13,23–25 We show that Ion
Proton sequencing is appropriate for NIPT and can reliably detect
fetal trisomy 13, 18 and 21.We and others recently showed that this
technology is equally suitable for other shallow sequencing-based
applications.51,52 The seqFF method for detecting the fetal fraction
in maternal plasma, regardless the fetal gender, was successfully
applied to our Ion Proton NIPT data. This method showed a high
correlation (r=0.909) with the fetal fraction calculation based on
Y chromosome sequences (FF-Y). This shows that although the
seqFF method was originally generated for Illumina technologies,
it can be applied to Proton data and can be used for fetal DNA
fraction measurements. Moreover, by including the read length
distribution inherent to Ion Proton sequencing, we can improve
the fetal fraction prediction even more (r=0.926).
In conclusion, we demonstrate that semiconductor
sequencing is very well suited for the implementation of
NIPT in a diagnostic genetic laboratory. Moreover, we have
shown that whole chromosome proﬁling is advantageous
to reduce the number of false positive and false negative
results. The implementation of an easily established fetal
fraction calculation for all pregnancies improves reliability
of NIPT and is useful for the interpretation of Z-scores.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Non-invasive prenatal testing (NIPT) for fetal aneuploidies has been
applied worldwide and is mainly offered by commercial service
providers.
WHAT DOES THIS STUDY ADD?
• This study demonstrates the performance of non-invasive prenatal
testing in a genetic laboratory by semiconductor sequencing.
• Advantages of fetal fraction calculation and comprehensive
chromosome proﬁling are discussed in this article and illustrated
by several clinical examples.
REFERENCES
1. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal
chromosomal aneuploidy by massively parallel genomic sequencing of
DNA in maternal plasma. Proc Natl Acad Sci U S A 2008;105:20458–63.
Figure 5 Maternal duplication on chromosome 13 leads to false positive trisomy 13 call. Comprehensive chromosome proﬁle of chromosome
13 for case_15 showing a duplication (in blue) on chromosome band 13q21.33. The log2 ratio of the duplication is higher than expected for a
fetal cfDNA aberration (fetal fraction 12.30%), hence pointing to a duplication of maternal origin
NIPT implementation in a genetic lab 705
Prenatal Diagnosis 2016, 36, 699–707 © 2016 The Authors. Prenatal Diagnosis published by John Wiley & Sons, Ltd.
2. Fan HC, Blumenfeld YJ, Chitkara U, et al. Noninvasive diagnosis of fetal
aneuploidy by shotgun sequencing DNA frommaternal blood. Proc Natl
Acad Sci U S A 2008;105:16266–71.
3. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal
assessment of trisomy 21 by multiplexed maternal plasma DNA
sequencing: large scale validity study. BMJ 2011;342:c7401.
4. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal
Evaluation (NICE) Study: results of a multicenter prospective cohort
study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet
Gynecol 2012;207:137.e1–8.
5. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy
detection by maternal plasma DNA sequencing. Obstet Gynecol
2012;119:890–901.
6. Mccullough RM, Almasri EA, Guan X, et al. Non-invasive prenatal
chromosomal aneuploidy testing—clinical experience: 100 000 clinical
samples. PLoS One 2014;9:e109173.
7. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus
standard prenatal aneuploidy screening. N Engl J Med 2014;370:799–808.
8. Zhang H, Gao Y, Jiang F, et al. Non-invasive prenatal testing for
trisomies 21, 18 and 13: clinical experience from 146 958 pregnancies.
Ultrasound Obstet Gynecol 2015;45:530–8.
9. NortonME, JacobssonB, SwamyGK, et al. Cell-free DNA analysis for
noninvasive examination of trisomy. N Engl J Med 2015;372:1589–97.
10. Zhao C, Tynan J, Ehrich M, et al. Detection of fetal subchromosomal
abnormalities by sequencing circulating cell-free DNA from maternal
plasma. Clin Chem 2015;61:608–16.
11. BradyP, BrisonN, Van Den BogaertK, et al. Clinical implementation of
NIPT— technical and biological challenges. Clin Genet 2016;89(5):523–30,
DOI:10.1111/cge.12598.
12. Vora NL, O’brien BM. Noninvasive prenatal testing for microdeletion
syndromes and expanded trisomies: proceed with caution. Obstet
Gynecol 2014;123:1097–9.
13. Yin AH, Peng CF, Zhao X, et al. Noninvasive detection of fetal
subchromosomal abnormalities by semiconductor sequencing of
maternal plasma DNA. Proc Natl Acad Sci U S A 2015;24;112(47):14670–5,
DOI: 10.1073/pnas.1518151112.
14. Lo KK, Karampetsou E, Boustred C, et al. Limited clinical utility of non-
invasive prenatal testing for subchromosomal abnormalities. Am J Hum
Genet 2016;98(1):34–44, DOI: 10.1016/j.ajhg.2015.11.016.
15. Juneau K, Bogard PE, Huang S, et al. Microarray-based cell-free DNA
analysis improves noninvasive prenatal testing. Fetal Diagn Ther
2014;36:282–6.
16. Stokowski R, Wang E, White K, et al. Clinical performance of non-invasive
prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal
plasma with microarrays or next generation sequencing (NGS) is consistent
across multiple controlled clinical studies. Prenat Diagn 2015;35(12):1243–6,
DOI: 10.1002/pd.4686.
17. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal
aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted
sequencing of polymorphic loci. Prenat Diagn 2012;32:1233–41.
18. Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection
and selective analysis of cell-free DNA obtained from maternal blood:
evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol
2012;206:319.e1–9.
19. Scheinin I, Sie D, Bengtsson H, et al. DNA copy number analysis of fresh
and formalin-ﬁxed specimens by shallow whole-genome sequencing
with identiﬁcation and exclusion of problematic regions in the genome
assembly. Genome Res 2014;24:2022–32.
20. Straver R, Sistermans EA, Reinders MJ. Introducing WISECONDOR
for noninvasive prenatal diagnostics. Expert Rev Mol Diagn
2014;14:513–5.
21. Straver R, Sistermans EA, Holstege H, et al. WISECONDOR: detection of
fetal aberrations from shallow sequencing maternal plasma based on a
within-sample comparison scheme. Nucleic Acids Res 2014;42:e31.
22. Lo KK, Boustred C, Chitty LS, et al. RAPIDR: an analysis package for
non-invasive prenatal testing of aneuploidy. Bioinformatics
2014;30:2965–7.
23. YuanY, JiangF, HuaS, et al. Feasibility study of semiconductor sequencing
for noninvasive prenatal detection of fetal aneuploidy. Clin Chem
2013;59:846–9.
24. Liao C, Yin AH, Peng CF, et al. Noninvasive prenatal diagnosis of
common aneuploidies by semiconductor sequencing. Proc Natl Acad
Sci U S A 2014;111:7415–20.
25. Jeon YJ, Zhou Y, Li Y, et al. The feasibility study of non-invasive fetal
trisomy 18 and 21 detection with semiconductor sequencing platform.
PLoS One 2014;9:e110240.
26. Vora NL, Johnson KL, Basu S, et al. A multifactorial relationship exists
between total circulating cell-free DNA levels and maternal BMI. Prenat
Diagn 2012;32:912–4.
27. Ashoor G, Syngelaki A, Poon LC, et al. Fetal fraction in maternal plasma
cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal
characteristics. Ultrasound Obstet Gynecol 2013;41:26–32.
28. Benn P, Cuckle H. Theoretical performance of non-invasive prenatal
testing for chromosome imbalances using counting of cell-free DNA
fragments in maternal plasma. Prenat Diagn 2014;34:778–83.
29. Chan KC, Zhang J, Hui AB, et al. Size distributions of maternal and fetal
DNA in maternal plasma. Clin Chem 2004;50:88–92.
30. Fan HC, Blumenfeld YJ, Chitkara U, et al. Analysis of the size
distributions of fetal and maternal cell-free DNA by paired-end
sequencing. Clin Chem 2010;56:1279–86.
31. Yu SC, Chan KC, Zheng YW, et al. Size-based molecular diagnostics
using plasma DNA for noninvasive prenatal testing. Proc Natl Acad Sci
U S A 2014;111:8583–8.
32. Kim SK, Hannum G, Geis J, et al. Determination of fetal DNA fraction
from the plasma of pregnant women using sequence read counts.
Prenat Diagn 2015;35:810–5.
33. Faas BH, De Ligt J, JanssenI, et al. Non-invasive prenatal diagnosis
of fetal aneuploidies using massively parallel sequencing-by-ligation
and evidence that cell-free fetal DNA in the maternal plasma
originates from cytotrophoblastic cells. Expert Opin Biol Ther
2012;12(Suppl 1):S19–26.
34. Grati FR, Malvestiti F, Ferreira JC, et al. Fetoplacental mosaicism:
potential implications for false-positive and false-negative noninvasive
prenatal screening results. Genet Med 2014;16:620–4.
35. Lau TK, Jiang FM, Stevenson RJ, et al. Secondary ﬁndings from
non-invasive prenatal testing for common fetal aneuploidies by
whole genome sequencing as a clinical service. Prenat Diagn
2013;33:602–8.
36. Snyder MW, Simmons LE, Kitzman JO, et al. Copy-number variation
and false positive prenatal aneuploidy screening results. N Engl J Med
2015;372:1639–45.
37. Zhang H, Zhao YY, Song J, et al. Statistical approach to decreasing the
error rate of noninvasive prenatal aneuploid detection caused by
maternal copy number variation. Sci Rep 2015;5:16106.
38. Osborne CM, Hardisty E, Devers P, et al. Discordant noninvasive
prenatal testing results in a patient subsequently diagnosed with
metastatic disease. Prenat Diagn 2013;33:609–11.
39. Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive prenatal testing
and incidental detection of occult maternal malignancies. JAMA
2015;314:162–9.
40. Amant F, Verheecke M, Wlodarska I, et al. Presymptomatic
identiﬁcation of cancers in pregnant women during noninvasive
prenatal testing. JAMA Oncol 2015;1:814–9.
41. Sante T, Vergult S, Volders PJ, et al. ViVar: a comprehensive platform for
the analysis and visualization of structural genomic variation. PLoS One
2014;9:e113800.
42. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA
sequencing of maternal plasma to detect Down syndrome: an
international clinical validation study. Genet Med 2011;13:913–20.
43. Jensen TJ, Zwiefelhofer T, Tim RC, et al. High-throughput massively
parallel sequencing for fetal aneuploidy detection from maternal
plasma. PLoS One 2013;8:e57381.
44. Hudecova I, Sahota D, Heung MM, et al. Maternal plasma fetal DNA
fractions in pregnancies with low and high risks for fetal chromosomal
aneuploidies. PLoS One 2014;9:e88484.
45. Hsu WT, Shchepin DA, Mao R, et al. Mosaic trisomy 16 ascertained
through amniocentesis: evaluation of 11 new cases. Am J Med Genet
1998;80:473–80.
46. Neiswanger K, Hohler PM, Hively-Thomas LB, et al. Variable outcomes
in mosaic trisomy 16: ﬁve case reports and literature analysis. Prenat
Diagn 2006;26:454–61.
47. Petracchi F, Igarzabal L, Crespo ML, et al. Trisomy 16 detected by ﬁrst
trimester screening. Prenat Diagn 2009;29:1175–6.
48. Benn P. Trisomy 16 and trisomy 16 mosaicism: a review. Am J Med
Genet 1998;79:121–33.
A. Dheedene et al.706
Prenatal Diagnosis 2016, 36, 699–707 © 2016 The Authors. Prenatal Diagnosis published by John Wiley & Sons, Ltd.
49. Chareonsirisuthigul T, Worawichawong S, Parinayok R, et al.
Intrauterine growth retardation fetus with trisomy 16 mosaicism. Case
Rep Genet 2014;2014:739513.
50. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in
maternal plasma and serum: implications for noninvasive prenatal
diagnosis. Am J Hum Genet 1998;62:768–75.
51. Chen S, Li S, Xie W, et al. Performance comparison between rapid
sequencing platforms for ultra-low coverage sequencing strategy. PLoS
One 2014;9:e92192.
52. Deleye L, Dheedene A, De Coninck D, et al. Shallow whole genome
sequencing is well suited for the detection of chromosomal aberrations
in human blastocysts. Fertil Steril 2015;104:1276–85 e1.
SUPPORTING INFORMATION
Additional supporting information may be found in the online
version of this article at the publisher’s web site.
NIPT implementation in a genetic lab 707
Prenatal Diagnosis 2016, 36, 699–707 © 2016 The Authors. Prenatal Diagnosis published by John Wiley & Sons, Ltd.
